Healthcare Industry News: RNAi therapeutic
News Release - September 9, 2009
EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial OfficerWATERTOWN, Mass., Sept. 9 -- (Healthcare Sales & Marketing Network) -- EnVivo Pharmaceuticals today announced the appointment of Stephen J. DiPalma as senior vice president and chief financial officer. DiPalma is responsible for overall financial operations for EnVivo including financial analysis, accounting and operations.
"EnVivo has grown to the point where we have created a CFO position to help better manage our broad pipeline and increasing business opportunities," said Kees Been, CEO of EnVivo. "Steve brings a broad skill set and a proven track record to the position that combines a strategic business perspective and an entrepreneurial spirit. We anticipate his 25 years of experience to be a great asset to EnVivo at this important time for our company."
Most recently, DiPalma was Executive Vice President of Business Operations and CFO for RXi Pharmaceuticals Corporation, a company focusing on RNAi therapeutics that he helped to bring public. He was also Co-founder, President and CEO of Catalyst Oncology which focused on personalized medicine approaches for multiple forms of cancer. Prior to RXi and Catalyst Oncology, DiPalma served as CFO at companies including Milkhaus Laboratories, Phytera, Aquila Biopharmaceuticals and Athena Diagnostics.
DiPalma has an MBA, with concentrations in finance and accounting, from Babson College, and received a Bachelor of Science degree in Business Administration from the University of Massachusetts.
About EnVivo Pharmaceuticals
EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Cognitive Disorders and Schizophrenia. The company's lead product is EVP-6124, an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase IIa clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase I studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for schizophrenia). For more information about EnVivo, visit www.envivopharma.com.
Source: EnVivo Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.